Key Takeaways
- Biotalys reported a €15.8 million net loss for 2025, up from €13.2 million in 2024, with a year-end cash balance of €8.0 million and a financial runway extending to end of May 2026.
- The company is proceeding with a strategic refocus to concentrate resources on its highest-priority biofungicide programs while suspending early-stage activities.
- EVOCA received U.S. EPA approval in December 2025 and Florida state registration in April 2026, making it the first AGROBODY biocontrol approved by a U.S. state.
- Biotalys entered a strategic partnership with 21st.BIO to accelerate production of its protein-based biocontrol solutions at commercially competitive costs.
- EVOCA NG is planned for U.S. launch in 2029 and European launch in 2030, targeting a combined market of more than $1.1 billion.
Biotalys Reaches Value Inflection Point With EVOCA Approval, Sharpens Strategic Focus
Biotalys (Euronext: BTLS) has reported its 2025 full-year financial results alongside a strategic refocus announced in early February 2026. Interim CEO Carlo Boutton described 2025 as a major value inflection point for the company, anchored by U.S. EPA approval of EVOCA — its first biocontrol and the first product validated under the company's AGROBODY™ platform. In April 2026, EVOCA received Florida state registration, marking the first approval of an AGROBODY biocontrol at the U.S. state level. California registration is expected in the second half of 2026.
The strategic refocus, now confirmed by the Biotalys board, will concentrate the company's resources on its lead biofungicide assets — EVOCA, EVOCA NG, and BioFun-6 — while suspending early-stage activities and implementing a streamlined operating model designed to materially reduce cash burn.
Biotalys 2025 Financial Results
Biotalys reported a net loss of €15.8 million for 2025, compared to €13.2 million in 2024. Research and development expenses rose to €13.3 million from €11.0 million, driven by increased external spending on strain engineering and field trials. General and administrative expenses declined slightly to €5.6 million. Other operating income of €3.0 million included R&D tax incentives, grants, and recognized partner fees. Basic and diluted loss per share was €0.42, compared to €0.40 in 2024. Cash and cash equivalents stood at €8.0 million at year-end, down from €22.6 million at end-2024, with net annual cash burn increasing 8% to €14.6 million.
The company confirms its current financial runway extends to end of May 2026 and says it is in well-advanced negotiations with investors to support the strategic refocus, exploring both equity and alternative dilutive and non-dilutive financing options.
EVOCA Pipeline and European Regulatory Progress
In Europe, the Dutch Board for the Authorisation of Plant Protection Products recommended approval of EVOCA's active ingredient across the EU, and the Dutch Institute for Health and Environment confirmed no critical areas of concern, proposing a low-risk classification. EFSA has initiated a two-month public consultation period, expected to conclude by end of June, after which the dossier will proceed to the decision phase.
The EPA approval of EVOCA clears a regulatory pathway for EVOCA NG, the product's next-generation formulation containing the same active ingredient. Biotalys expects a significantly shorter regulatory review for EVOCA NG. Commercial launch is planned in the USA in 2029 and in Europe in 2030, targeting a combined market of more than $1.1 billion.
Biotalys Pipeline Advances Across Multiple Programs
BioFun-6, Biotalys' second biofungicide candidate, achieved the same performance level as EVOCA in initial field trials at significantly lower dosage rates, with additional results from a second lead candidate expected by mid-2026. BioIns-2, developed in collaboration with Syngenta Crop Protection, reached a first research milestone in April 2026. The Gates Foundation-partnered BioFun-7 program targeting leafspot disease continues to progress, and Biotalys is opening BioFun-4 and BioFun-8 for external R&D collaboration.
21st.BIO Partnership Targets Commercially Competitive Manufacturing
In early 2026, Biotalys entered a strategic partnership with 21st.BIO, a Danish precision fermentation technology company, to accelerate production of its AGROBODY biocontrol products at commercially competitive costs. Strain engineering and process development for both EVOCA and BioFun-6 is on track to meet commercial timelines, with important progress expected in Q4 2026 that will allow Biotalys to initiate required regulatory studies for EVOCA NG.
Read the complete financial results here.
4 Comments